Floatz logo

Zilovertamab

Immunoproliferative Disorders

Oncternal Therapeutics, Incmonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Immunoproliferative Disorders cohort.

Asset / SponsorPhaseRating
Ibrutinib
Oncternal Therapeutics, Inc
Phase 3B
Jcar017 (Lisocabtagene Maraleucel)
Juno Therapeutics, a Subsidiary of Celgene
Phase 2B
Tucidinostat
Fudan University
Phase 2CCC
Oricar-017
OriCell Therapeutics Co., Ltd.
Phase 1CC
Fludarabine
UNC Lineberger Comprehensive Cancer Center
Phase 1CC

View all 12 →

Same molecule, other indications

Zilovertamab is also rated in:

mantle cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
lymphoproliferative syndromeDormant
B
Indicative ·
60 / 100
View asset →
lymphatic system disorderDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →